Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV002519088 | SCV003934935 | likely benign | Angelman syndrome | 2023-06-16 | reviewed by expert panel | curation | The allele frequency of the c.1668G>A p.Val556= variant in UBE3A (NM_130838.2) is 0.008% in the African/African American sub population in gnomAD, which is high enough to meet the BS1 criteria based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). The silent p.Val556= variant is not predicted to affect splicing using multiple computational tools and does not affect a highly conserved nucleotide (BP4, BP7). In summary, the c.1668G>A p.Val556= variant in UBE3A is classified as Likely Benign based on the ACMG/AMP criteria (BS1, BP4, BP7). |
Eurofins Ntd Llc |
RCV000345041 | SCV000332171 | uncertain significance | not provided | 2015-06-12 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000345041 | SCV000969093 | likely benign | not provided | 2018-05-23 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Labcorp Genetics |
RCV002519088 | SCV003263261 | likely benign | Angelman syndrome | 2025-01-30 | criteria provided, single submitter | clinical testing |